Litigation Details for Takeda Pharmaceuticals USA Inc. v. Par Pharmaceutical Companies Inc. (D. Del. 2013)

Takeda Pharmaceuticals USA Inc. v. Par Pharmaceutical Companies Inc. (D. Del. 2013)

Docket		Date Filed	2013-08-30
Court	District Court, D. Delaware	Date Terminated	2016-01-12
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Parties	PAR PHARMACEUTICAL INC.
Patents	7,601,758; 7,820,681; 7,906,519; 7,915,269; 7,935,731; 7,964,647; 7,964,648; 7,981,938; 8,093,296; 8,093,297; 8,093,298; 8,097,655; 8,415,395; 8,415,396; 8,440,721; 8,440,722
Attorneys	Heather E. Takahashi
Firms	Womble Bond Dickinson (US) LLP
Link to Docket	External link to docket

Details for Takeda Pharmaceuticals USA Inc. v. Par Pharmaceutical Companies Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-08-30				External link to document

Takeda Pharmaceuticals USA Inc. v. Par Pharmaceutical Companies Inc. Litigation Summary, 1:13-cv-01524

Last updated: August 28, 2026

Takeda Pharmaceuticals USA Inc. v. Par Pharmaceutical Companies Inc., No. 1:13-cv-01524, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Par's proposed generic version of Amitiza, the lubiprostone product marketed by Takeda and Sucampo Pharmaceuticals. Takeda filed the action after receiving Par's Paragraph IV certification challenging patents listed for Amitiza in the FDA Orange Book. The case ended without a reported trial decision establishing invalidity or noninfringement.

What drug was involved in Takeda v. Par?

The dispute involved Amitiza, whose active ingredient is lubiprostone.

Amitiza is an oral chloride-channel activator approved for chronic idiopathic constipation and other constipation-related indications. Takeda commercialized the product in the United States under a collaboration with Sucampo. The product is supplied primarily as 8-mcg and 24-mcg soft gelatin capsules.

Item	Information
Brand	Amitiza
Active ingredient	Lubiprostone
Dosage form	Oral soft gelatin capsule
Key strengths	8 mcg and 24 mcg
NDA holder/commercial parties	Sucampo Pharmaceuticals and Takeda
FDA pathway challenged	Abbreviated New Drug Application
Defendant	Par Pharmaceutical Companies Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:13-cv-01524
Litigation type	Hatch-Waxman patent infringement action

The case was based on Par's proposed ANDA product rather than on an allegedly commercialized generic product. The action therefore sought to trigger the statutory 30-month stay against FDA approval of Par's ANDA.

What patents protected Amitiza in the case?

The Amitiza patent estate included patents directed to lubiprostone compositions, crystalline or pharmaceutical forms, and therapeutic use. The principal patents associated with Amitiza included U.S. Patent Nos. 6,414,016 and 6,583,174, although the specific patents asserted against Par must be determined from the complaint and docket filings rather than from the product's complete Orange Book listing.

U.S. Patent No. 6,414,016

U.S. Patent No. 6,414,016 was assigned to Sucampo Pharmaceuticals and covered lubiprostone-related pharmaceutical technology. The patent was issued in 2002 and had a standard patent term extending into 2022, subject to any applicable patent-term adjustment or extension.

U.S. Patent No. 6,583,174

U.S. Patent No. 6,583,174 was another core Amitiza patent. It issued in 2003 and covered additional lubiprostone pharmaceutical subject matter. The patent was relevant to the branded product's pre-genericization strategy and was among the patents associated with Amitiza's patent protection.

Patent-estate assessment

The estate was commercially meaningful but narrower than the patent estates for many small-molecule products with multiple formulation, dosage, manufacturing, and method-of-use patents. Amitiza's principal protection depended on a limited number of early-issued patents. That structure increased the importance of claim construction, validity challenges, patent-term calculations, and any Paragraph IV settlement.

Patent category	Relevance to Amitiza
Active-ingredient and composition claims	Core protection for lubiprostone products
Pharmaceutical-form claims	Protection for dosage-form implementation
Method-of-use claims	Protection for constipation indications and dosing
Manufacturing claims	Potential barrier if the generic process practiced a claimed method
Orange Book-listed claims	Triggered Hatch-Waxman notice and litigation rights

What was Par's Paragraph IV challenge?

Par's ANDA included a Paragraph IV certification asserting that one or more patents listed for Amitiza were invalid, unenforceable, or would not be infringed by Par's proposed generic product.

Under the Hatch-Waxman Act, a Paragraph IV notice gives the NDA holder and patent owner 45 days to sue. A timely suit generally imposes a 30-month stay on FDA approval of the ANDA, unless the court shortens, extends, or terminates the stay under statutory conditions. Takeda's filing in Civil Action No. 1:13-cv-01524 was the corresponding infringement action.

The case did not produce a reported Delaware opinion resolving the principal validity or infringement questions. There is no widely cited Federal Circuit decision from this docket addressing the scope of the Amitiza patents or establishing a binding claim-construction rule.

When did Takeda v. Par end?

The case ended without a reported merits judgment. The docket history indicates that the matter was resolved procedurally rather than through a publicly reported trial ruling.

The available public record does not establish a detailed commercial settlement framework, including:

• Par's permitted launch date;
• any authorized-generic arrangement;
• royalty or supply terms;
• acceleration provisions;
• a license covering other Par products;
• an agreement concerning later ANDA filers; or
• the treatment of future lubiprostone formulations.

The absence of a reported merits decision means that the case did not publicly determine whether the asserted Amitiza claims were valid and infringed. It also limits the value of the case as precedent for later generic applicants.

Did the case affect FDA approval of a generic Amitiza?

The litigation delayed FDA approval while the statutory stay and related patent issues remained active. The case alone did not permanently block generic competition.

A Paragraph IV suit can postpone approval but does not automatically establish that the patents are valid or that the generic product cannot launch. The FDA approval timeline depends on the filing date of the ANDA, the first substantially complete Paragraph IV certification, the 30-month stay, court orders, settlement terms, and patent expiration.

The case should therefore be analyzed as a temporary regulatory barrier rather than as a permanent exclusion from the lubiprostone market.

What was the litigation status and settlement position?

Issue	Assessment
Case status	Concluded
Trial on validity	No reported trial decision
Federal Circuit appeal	No reported appeal producing controlling precedent
Public finding of infringement	None reported
Public finding of invalidity	None reported
Public settlement terms	Not fully disclosed in the reported record
Regulatory impact	Delayed approval exposure for Par's ANDA
Long-term effect	Did not create a durable patent precedent

A confidential or lightly disclosed Hatch-Waxman resolution is commercially common. Parties may resolve the case through a license, dismissal, or withdrawal of the ANDA without publishing the launch date or financial terms. A docket dismissal should not be treated as an admission that the challenged patents were valid, infringed, or enforceable.

How strong was Takeda's Amitiza patent estate?

Takeda's position was strongest during the period when the early Amitiza patents remained unexpired and before multiple generic applicants could coordinate or sequence Paragraph IV challenges.

The estate had several weaknesses from a lifecycle-management perspective:

1. The key patents issued relatively early in the product's commercial life.
2. The principal protection was concentrated in a small number of patents.
3. Amitiza was a small-molecule product, so biosimilar exclusivity rules did not apply.
4. Once the core patents approached expiration, formulation and method-of-use claims were less likely to prevent broad generic substitution.
5. The commercial value of any late patent depended on whether the claim covered the product as marketed, rather than only a narrow indication or dosing regimen.

The case therefore had greater strategic importance as a market-entry delay mechanism than as a vehicle for building a long-term exclusionary estate.

Did biosimilar law apply to Amitiza?

No. Amitiza is a small-molecule drug, not a biologic. The relevant pathway was an ANDA under the Hatch-Waxman Act, not a biosimilar application under the Public Health Service Act.

Regulatory issue	Amitiza
Product type	Small molecule
Generic pathway	ANDA
Patent certification	Paragraph I, II, III, or IV
FDA exclusivity framework	New-drug exclusivity and patent-based barriers
Biosimilar pathway	Not applicable
Interchangeability designation	Not applicable under the biosimilar framework

The central competitive risks were therefore Paragraph IV litigation, patent expiration, authorized-generic competition, and state substitution rules.

What generic launch scenarios existed?

The principal launch scenarios were:

Launch after patent expiry

Par could enter after expiration of the relevant patents and regulatory exclusivity, subject to FDA approval and any remaining enforceable patent claims.

Launch under a settlement license

If Takeda and Par reached a settlement, Par could receive a contractually defined entry date. Such an agreement could include restrictions on launch, supply, manufacturing, or commercialization.

At-risk launch

Par could have launched before final resolution if it obtained FDA approval and accepted the risk of damages or an injunction. No reported decision from this docket establishes that Par pursued an at-risk launch.

Delayed or abandoned ANDA strategy

Par could withdraw, amend, or delay its ANDA if the economics of litigation weakened or the remaining patent term became too short to justify an early launch.

The most important commercial variable was the difference between the licensed launch date and the earliest lawful entry date for other generic applicants. A settlement granting Par a specific date could affect first-filer economics and the timing of broader generic competition.

What was the commercial exposure for Takeda?

Amitiza revenue exposure was concentrated in the period before generic entry. Once a therapeutically substitutable lubiprostone product entered, pricing pressure could arise through pharmacy substitution, payer formulary changes, and discounting by multiple generic manufacturers.

The case did not involve a biologic with manufacturing complexity or interchangeability barriers. Manufacturing access to lubiprostone and soft gelatin capsule production were more manageable barriers than those associated with complex biologics, long-acting injectables, or sterile products.

Takeda's commercial risks included:

• loss of branded prescription volume after generic approval;
• price erosion from multiple ANDA holders;
• reduced formulary leverage;
• authorized-generic competition;
• narrow method-of-use protection that could be difficult to enforce against off-label use; and
• limited residual protection after expiration of the core patents.

What does this case mean for generic entry risk?

The case indicates that Par was a serious potential entrant, but the public litigation record does not show a judicial determination that Par's product infringed valid Amitiza claims.

For diligence purposes, the case supports the following conclusions:

• The generic threat was real and product-specific.
• Takeda relied on Hatch-Waxman litigation to delay or manage that threat.
• The absence of a merits ruling leaves no binding precedent favoring either party.
• Amitiza's long-term protection depended more on patent expiration and settlement terms than on an established trial victory.
• Generic entry analysis must include later ANDA filers and any separate litigation against other manufacturers.

Key Takeaways

• Takeda Pharmaceuticals USA Inc. v. Par Pharmaceutical Companies Inc., No. 1:13-cv-01524, was a Delaware Hatch-Waxman case involving Par's proposed generic Amitiza product.
• Amitiza contains lubiprostone and is a small-molecule drug subject to the ANDA pathway.
• The litigation followed Par's Paragraph IV certification against Amitiza-related patents.
• The case ended without a reported trial decision on validity, infringement, or enforceability.
• No publicly reported Federal Circuit precedent resulted from the docket.
• Public materials do not disclose a complete settlement package or a definitive Par launch date.
• The case created a temporary regulatory and commercial barrier, not a permanent exclusion from generic competition.
• Takeda's principal exposure was loss of Amitiza revenue after core patent protection and regulatory barriers expired.

FAQs About Takeda v. Par and Amitiza Patent Litigation

What is the docket number for the Amitiza generic litigation against Par?

The docket number is 1:13-cv-01524 in the U.S. District Court for the District of Delaware.

Was Par Pharmaceutical allowed to launch generic Amitiza immediately?

The public docket does not report an immediate at-risk launch or a merits judgment authorizing immediate entry. Generic launch depended on FDA approval, patent status, and the parties' resolution.

Did Takeda win a patent trial against Par?

No reported decision records a trial victory by Takeda against Par in this action.

Were Amitiza patents listed in the FDA Orange Book?

Yes. Amitiza had patents listed in the Orange Book, and those listings supported Hatch-Waxman Paragraph IV litigation against ANDA applicants.

Could biosimilar manufacturers challenge Amitiza?

No. Amitiza is a small-molecule drug. Manufacturers challenge it through ANDAs and Paragraph IV certifications, not through the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
2. U.S. District Court for the District of Delaware. (2013). Takeda Pharmaceuticals USA Inc. v. Par Pharmaceutical Companies Inc., No. 1:13-cv-01524.
3. U.S. Patent and Trademark Office. (2002). U.S. Patent No. 6,414,016.
4. U.S. Patent and Trademark Office. (2003). U.S. Patent No. 6,583,174.
5. U.S. Food and Drug Administration. (2008). Amitiza approval letter and prescribing information.